Gain Therapeutics, Inc. GANX
- GT-02287 — Parkinson's Disease Phase 1
- GT-02287 — Gaucher Disease Preclinical
- GT-02287 — Dementia with Lewy Bodies Preclinical
- GT-02287 — Alzheimer's Disease Preclinical
Home › Targets › glucocerebrosidase
glucocerebrosidase (1 companies · 4 programs)
Companies with an active program directed at glucocerebrosidase.